India Market Growth and Financial Performance
Q3 FY24: Key Developments
Consistent trajectory of improved profitability
Financials
Sales and Adj. EBITDA* Trajectory
45,369 49,392 50,799
42,446 43,303
20.1%
18.7%
13.9% 14.4%
12.2%
LUPIN
Complex Generics
Gaining
momentum
gProlensa
Ophthalmic
Solution
Launched in
US
gSpiriva
DPI
Business Development
India - Launched 1st triple FDC for COPD under brand
name Vilfuro-G®
Middle East - Exclusive Licensing and Supply Agreement
with Amman Pharma for Ranibizumab Biosimilar
Compliance
Q3
Q4
Q1
Q2
FY23 FY23
FY24 FY24
Q3
FY24
US FDA
Sales
EBITDA margin**
*excludes NCE, Fx and Other Income
** EBITDA margins excludes NCE, Fx and Other Income
on Net Sales as base
Others
Remediation completed for Tarapur &
Mandideep Unit 1
Aurangabad received SMDC approval
(Ukraine)
5View entire presentation